For example, miR-638 regulates cell differentiation and proliferation by targeting cyclin-dependent kinase 2 (CDK-2) in leukemic cells [15]; and in BRCA1-deficient triple negative breast cancer tumors, miR-638 and miR-146 were suggested to perform as potential biomarkers for improved overall survival [14]. Here, CDK2 is linked to triple-negative breast carcinoma.